Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)

NCT03810066 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
EGFR T790M
FDG-PET

Interventions

DRUG: Osimertinib

Sponsor

University Hospital, Essen